Risk factors of death in mechanically ventilated COVID-19 patients: a retrospective multi-center study
Salehi et al.,
Risk factors of death in mechanically ventilated COVID-19 patients: a retrospective multi-center study,
Research Square, doi:10.21203/rs.3.rs-1362678/v1 (Preprint)
Retrospective 125 mechanically ventilated ICU patients in Iran, showing no significant difference with HCQ treatment in unadjusted results.
This study is excluded in the after exclusion results of meta
analysis:
unadjusted results with no group details.
risk of death, 14.5% higher, RR 1.14, p = 0.44, treatment 53 of 86 (61.6%), control 21 of 39 (53.8%).
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Salehi et al., 11 Mar 2022, retrospective, Iran, preprint, mean age 62.0, 11 authors, study period April 2021 - September 2021.
Abstract: Risk factors of death in mechanically ventilated
COVID-19 patients: a retrospective multi- center
study
Mohammadreza Salehi
Department of Infectious Disease, Imam Khomeini Hospital complex, Tehran University of Medical
Sciences
Mohammad-Taghi Beig Mohammadi
Department of Anesthesiology & critical care, Imam Khomeini Hospital complex, Tehran University of
Medical Sciences
Seyed Hamidreza Abtahi
Department of pulmonary and critical care medicine, Thoracic Research Center, Imam Khomeini
Hospital complex, Tehran University of Medical Sciences, Tehran. Iran
Samrand-Fattah Ghazi
Department of Anesthesiology & critical care, Imam Khomeini Hospital complex, Tehran University of
Medical Sciences
Abolfazl Sobati
Department of nursing and midwifery, Tehran University of Medical Sciences. Clinical Nurse, Imam
Khomeini Hospital Complex, Tehran, Iran
Rama Bozorgmehr
Shohada-e Tajrish Hospital, Shahid Beheshti University of Medical Sciences
Seyed Ali Dehghan Manshadi
Department of Infectious Disease, Imam Khomeini Hospital complex, Tehran University of Medical
Sciences
Saeed Reza Jamali Siahkali
Department of Infectious Disease, Ziaeian Hospital, Tehran University of Medical Sciences
Mostafa Mohammadi
Department of Anesthesiology & critical care, Imam Khomeini Hospital complex, Tehran University of
Medical Sciences
Banafsheh Moradmand Badie
Australasian Bone Marrow Transplant Recipient Registry (ABMTRR), Sydney, Australia
Ensiyeh Rahimi ( ensiyehrahimi@gmail.com )
Department of Infectious Disease, Imam Khomeini Hospital complex, Tehran University of Medical
Sciences
Page 1/22
Research Article
Keywords: COVID-19, mechanical ventilation, extubation, mortality risk factors
Posted Date: March 11th, 2022
DOI: https://doi.org/10.21203/rs.3.rs-1362678/v1
License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Page 2/22
Abstract
Introduction: Despite the improvement in COVID-19 therapeutic management the mortality of
mechanically ventilated COVID-19 patients remains high. In this study, we determined risk factors of
mortality in these cases.
Methods: This retrospective study examined clinical and paraclinical data of COVID-19 patients
mechanically ventilated at the time of hospitalization to ICU admission until death or discharge from
hospital between April and September in 2021 in three COVID-19 referral hospitals.
Results: One hundred twenty-five patients (60% male, mean age 62 ± 15.18, range 17 to 97 years old)
were recruited to this study. 51(40%) survived and 74 (60%) didn’t survive. At the time of hospital
admission, the vital signs were not significantly different between the survivors and non-survivors groups,
also diarrhea was not reported in non-survivors, but reported in 9.5% of survivors (P = 0.02). The mean
age of 74 non-survivors was higher than 51 survivors (65.1 ± 14.17 vs 56.9 ± 15.41, P = 0.003). The
intubation time since the patients were admitted to hospitals was not significantly different between the
two groups (3.38 ± 2.88 days vs 4.16 ± 3.42 days, P = 0.34). The mean LDH and D-dimer at the time of ICU
admission were significantly higher in the non-survivors group (863 ± 449 vs 613 ± 326, P = 0.01; 4081 ±
3342 vs 542 ± 634, P = 0.009; respectively). However, the mean CRP was not significantly different
between the two groups (76 ± 66.4, 54 ± 84.3; P = 0.1).
Mean APACHE-II score was higher in the non-survivors than the survivors (15 vs 13; P = 0.01). Use of
remdesivir,..
Late treatment
is less effective
salehi
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit